Evidence map›Paper›PMID 23787547›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2013

Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?

Jan Wysocki, Daniel Batlle

Abstract readComment
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.Clinical science (London, England : 1979) · 2021
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015
    Article
  10. ACE and ACE2 in kidney disease.World journal of nephrology · 2015
    Review
  11. Review
  12. ACE2 alterations in kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jan WysockiDivision of Nephrology/Hypertension, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Daniel Batlle

Funding

Strategies for ACE2 Amplification to Treat Diabetic Kidney DiseaseR01DK080089 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BATLLE, DANIEL · 2009 to 2012
$1.3M
NIDDK NIH HHS 1 R01 DK080089NIDDK NIH HHS R01 DK080089
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Kidney TransplantationRenal DialysisAngiotensin-Converting Enzyme 2FemaleHumansMalePeptidyl-Dipeptidase ARenal Insufficiency, ChronicACE2 protein, humanAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase AACE2CKDenzyme activityhypertensionplasma

Identifiers

PMID23787547
PMCPMC3769982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.